» Articles » PMID: 21516175

Integrated Analysis of Pharmacologic, Clinical and SNP Microarray Data Using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing

Overview
Specialty Biology
Date 2011 Apr 26
PMID 21516175
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We recently developed the Projection Onto the Most Interesting Statistical Evidence (PROMISE) procedure that uses prior biological knowledge to guide an integrated analysis of gene expression data with multiple biological and clinical endpoints. Here, PROMISE is adapted to the integrated analysis of pharmacologic, clinical and genome-wide genotype data. An efficient permutation-testing algorithm is introduced so that PROMISE is computationally feasible in this higher-dimension setting. In the analysis of a paediatric leukaemia data set, PROMISE effectively identifies genomic features that exhibit a biologically meaningful pattern of association with multiple endpoint variables.

Citing Articles

Statistical Methods Inspired by Challenges in Pediatric Cancer Multi-omics.

Cao X, H Elsayed A, Pounds S Methods Mol Biol. 2023; 2629:349-373.

PMID: 36929085 DOI: 10.1007/978-1-0716-2986-4_16.


Genetics of pleiotropic effects of dexamethasone.

Ramsey L, Pounds S, Cheng C, Cao X, Yang W, Smith C Pharmacogenet Genomics. 2017; 27(8):294-302.

PMID: 28628558 PMC: 5523978. DOI: 10.1097/FPC.0000000000000293.


CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints.

Cao X, Crews K, Downing J, Lamba J, Pounds S BMC Bioinformatics. 2016; 17(Suppl 13):382.

PMID: 27766934 PMC: 5073973. DOI: 10.1186/s12859-016-1217-0.


Cross-species genomic and epigenomic landscape of retinoblastoma.

Benavente C, McEvoy J, Finkelstein D, Wei L, Guolian Kang , Wang Y Oncotarget. 2013; 4(6):844-59.

PMID: 23765217 PMC: 3757242. DOI: 10.18632/oncotarget.1051.


Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Mitra A, Crews K, Pounds S, Cao X, Feldberg T, Ghodke Y J Pharmacol Exp Ther. 2011; 339(1):9-23.

PMID: 21712425 PMC: 3186292. DOI: 10.1124/jpet.111.182873.


References
1.
Campana D . Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23(5):1083-98, vii. PMC: 2762949. DOI: 10.1016/j.hoc.2009.07.010. View

2.
Coustan-Smith E, Ribeiro R, Stow P, Zhou Y, Pui C, Rivera G . A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood. 2006; 108(1):97-102. PMC: 1895825. DOI: 10.1182/blood-2006-01-0066. View

3.
Pui C, Campana D, Pei D, Bowman W, Sandlund J, Kaste S . Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360(26):2730-41. PMC: 2754320. DOI: 10.1056/NEJMoa0900386. View

4.
Sorich M, Pottier N, Pei D, Yang W, Kager L, Stocco G . In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008; 5(4):e83. PMC: 2292747. DOI: 10.1371/journal.pmed.0050083. View

5.
Rabbee N, Speed T . A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics. 2005; 22(1):7-12. DOI: 10.1093/bioinformatics/bti741. View